Karan S. Takhar - Net Worth and Insider Trading

Karan S. Takhar Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Karan S. Takhar owns 2 companies in total, including Zentalis Pharmaceuticals Inc (ZNTL) , and Aura Biosciences Inc (AURA) .

Click here to see the complete history of Karan S. Takhar’s form 4 insider trades.

Insider Ownership Summary of Karan S. Takhar

Ticker	Comapny	Transaction Date	Type of Owner
ZNTL	Zentalis Pharmaceuticals Inc	2020-04-03	director
AURA	Aura Biosciences Inc	2021-10-28	director

Karan S. Takhar Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Karan S. Takhar Ownership Network

Ownership Network List of Karan S. Takhar

No Data

Ownership Network Relation of Karan S. Takhar

Karan S. Takhar Owned Company Details

What does Zentalis Pharmaceuticals Inc do?

Who are the key executives at Zentalis Pharmaceuticals Inc?

Karan S. Takhar is the director of Zentalis Pharmaceuticals Inc. Other key executives at Zentalis Pharmaceuticals Inc include Chief Financial Officer Melissa B, Epperly , General Counsel Andrea Paul , and Chief Medical Officer Carrie Brownstein .

Zentalis Pharmaceuticals Inc (ZNTL) Insider Trades Summary

Over the past 18 months, Karan S. Takhar made no insider transaction in Zentalis Pharmaceuticals Inc (ZNTL). Other recent insider transactions involving Zentalis Pharmaceuticals Inc (ZNTL) include a net sale of 91,923 shares made by Cam Gallagher , a net sale of 24,575 shares made by Melissa B, Epperly , and a net sale of 96,375 shares made by Kevin D. Bunker .

In summary, during the past 3 months, insiders sold 12,953 shares of Zentalis Pharmaceuticals Inc (ZNTL) in total and bought 0 shares, with a net sale of 12,953 shares. During the past 18 months, 236,752 shares of Zentalis Pharmaceuticals Inc (ZNTL) were sold and 22,000 shares were bought by its insiders, resulting in a net sale of 214,752 shares.

Zentalis Pharmaceuticals Inc (ZNTL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zentalis Pharmaceuticals Inc Insider Transactions

No Available Data

Karan S. Takhar Mailing Address

Above is the net worth, insider trading, and ownership report for Karan S. Takhar. You might contact Karan S. Takhar via mailing address: C/o Zentalis Pharmaceuticals,inc., 530 Seventh Avenue, Suite 2201, New York Ny 10018.

Discussions on Karan S. Takhar

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.